Article
Exome-Based Genomic Markers Could Improve Prediction of Checkpoint Inhibitor Efficacy Independently of Tumor Type.
International journal of molecular sciences - 20 Apr 2023
Dalens Lorraine, Lecuelle Julie, Favier Laure, Fraisse Cléa, Lagrange Aurélie, Kaderbhai Courèche, Boidot Romain, Chevrier Sandy, Mananet Hugo, Derangère Valentin, Truntzer Caroline, Ghiringhelli François
Abstract excerpt
Immune checkpoint inhibitors (ICIs) have improved the care of patients in multiple cancer types. However, PD-L1 status, high Tumor Mutational Burden (TMB), and mismatch repair deficiency are the only validated biomarkers of efficacy for ICIs. These markers remain imperfect, and new predictive markers represent an unmet medical need. Whole-exome sequencing was carried out on 154 metastatic or locally advanced...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.